Mesa 3. Tratamiento

Mesa 3. Tratamiento

Dr. Bernardino

Alcázar Navarrete

Hospital de Alta Resolución de Loja.

Granada

Mesa 3. Tratamiento

Mesa 3

Tratamiento

Mesa 3. Tratamiento

GOLD guidelines, 2015

Mesa 3. Tratamiento

Miravitlles et al. Arch Bronconeumol 2014

Mesa 3. Tratamiento

Bateman et al. ERJ 2013

Mesa 3. Tratamiento

Dransfield, Lancet Resp Med 2013

Mesa 3. Tratamiento

Sin et al, Thorax 2010

Mesa 3. Tratamiento

Pascoe, Lancet Resp Med 2015

Mesa 3. Tratamiento

Magnussen et al. NEJM 2014

Mesa 3. Tratamiento

Mesa 3. Tratamiento

Dr. José Luis López-Campos

I [SEPAR] Utilidad de la vacunación antineumocócica de 13 serotipos en la prevención de exacerbaciones graves de EPOC I [ATS] QVA 149 Improves Lung Function To A Greater Extent Than Monocomponents In Patients With Moderate-To-Severe COPD: The FLIGHT 1 Study

Mesa 3. Tratamiento

Dr. Joan Serra

I [ATS] Effects Of 6 Weeks’ Treatment With Once-Daily Tiotropium And Olodaterol Fixed-Dose Combination On Inspiratory Capacity And Exercise Endurance In Patients With COPD: The MoractoTM Studies I [ATS] Withdrawal Of Inhaled Corticosteroids And Exacerbations Of COPD:The WISDOM Phenotyping SubstudyI [ERS] Triple therapy of umeclidinium and inhaledcorticosteroid/long-actingβ2-agonist (ICS/LABA) vs placebo + ICS/LABA in GOLD D patients

Mesa 3. Tratamiento

Dr. Juan Antonio Riesco

I [ATS] Inhaled Corticosteroids And Risk Of Incident Pneumonia And Mortality In Chronic Obstructive Pulmonary Disease (COPD) Patients: A Systematic Review And Meta-Analysis

I [ATS] COPD Patient Clusters That Benefit Most From Fluticasone Furoate Added To Vilanterol (FF/VI) vs Vilanterol (VI)

I [ERS] Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial

I [ERS] Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels

Mesa 3. Tratamiento

Dr. Carlos Amado

I [ATS] Stepwise Withdrawal Of Inhaled Corticosteroids in COPD Patients Receiving Dual Bronchodilators: Lung Function Reduction In The WISDOM Study I [ERS] Long-term efficacy of A1-PI therapy in RAPID and RAPID extension trials I [ATS] QVA 149 Provides Superior Improvement In Lung Function vs Its Monocomponents In Patients With Moderate-To-Severe COPD: The FLIGHT 2 Study

Mesa 3. Tratamiento

Muchas gracias

por su atención